These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 27292222)

  • 1. Nanomedicines for kidney diseases.
    Williams RM; Jaimes EA; Heller DA
    Kidney Int; 2016 Oct; 90(4):740-5. PubMed ID: 27292222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
    Muthu MS; Singh S
    Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicines for Renal Management: From Imaging to Treatment.
    Jiang D; Rosenkrans ZT; Ni D; Lin J; Huang P; Cai W
    Acc Chem Res; 2020 Sep; 53(9):1869-1880. PubMed ID: 32786331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Kidneys at the Nanoscale: Nanotechnology in Nephrology.
    Vasylaki A; Ghosh P; Jaimes EA; Williams RM
    Kidney360; 2024 Apr; 5(4):618-630. PubMed ID: 38414130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines for renal disease: current status and future applications.
    Kamaly N; He JC; Ausiello DA; Farokhzad OC
    Nat Rev Nephrol; 2016 Dec; 12(12):738-753. PubMed ID: 27795549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical and dental applications of nanomedicines.
    Kavoosi F; Modaresi F; Sanaei M; Rezaei Z
    APMIS; 2018 Oct; 126(10):795-803. PubMed ID: 30264432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern.
    Lam PL; Wong WY; Bian Z; Chui CH; Gambari R
    Nanomedicine (Lond); 2017 Feb; 12(4):357-385. PubMed ID: 28078952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
    Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
    Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle therapeutics for prostate cancer treatment.
    Sanna V; Sechi M
    Nanomedicine; 2012 Sep; 8 Suppl 1():S31-6. PubMed ID: 22640911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulus-responsive targeted nanomicelles for effective cancer therapy.
    Muthu MS; Rajesh CV; Mishra A; Singh S
    Nanomedicine (Lond); 2009 Aug; 4(6):657-67. PubMed ID: 19663594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicine: novel approaches in human and veterinary therapeutics.
    Irache JM; Esparza I; Gamazo C; Agüeros M; Espuelas S
    Vet Parasitol; 2011 Aug; 180(1-2):47-71. PubMed ID: 21680101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological principles underlying the kidney targeting of renal nanomedicines.
    Huang Y; Ning X; Ahrari S; Cai Q; Rajora N; Saxena R; Yu M; Zheng J
    Nat Rev Nephrol; 2024 Jun; 20(6):354-370. PubMed ID: 38409369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections.
    Lembo D; Donalisio M; Civra A; Argenziano M; Cavalli R
    Expert Opin Drug Deliv; 2018 Jan; 15(1):93-114. PubMed ID: 28749739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theranostic nanoparticles engineered for clinic and pharmaceutics.
    Ma X; Zhao Y; Liang XJ
    Acc Chem Res; 2011 Oct; 44(10):1114-22. PubMed ID: 21732606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated Regulatory Considerations for Nanomedicines.
    Subin TS; Vijayan V; Kumar KJR
    Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicines as cancer therapeutics: current status.
    Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
    Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Targeted nanomedicine in diagnostics and therapy of neurological diseases].
    Bertalan F; László B; Attila V
    Ideggyogy Sz; 2013 May; 66(5-6):155-63. PubMed ID: 23909015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theranostic nanomedicine.
    Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
    Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.